Cytosorbents Corp

Cytosorbents Corp maintains a capital structure characterized by high leverage and negative net cash. The company holds $6.25 million in cash and equivalents against $16.67 million in long-term debt, resulting in a debt-to-equity ratio of 2.82. Total liabilities stand at $38.28 million, significantly exceeding total equity of $5.90 million. The current liquidity position is assessed as medium risk, with the key flag noting that net cash is negative after subtracting total debt. The market capitalization is $23.36 million, implying a price-to-book ratio of 3.96.

Profitability metrics indicate significant operational challenges. The company reported a net loss of $8.20 million on revenue of $37.06 million, resulting in a return on equity of -200.73% and a return on assets of -26.82%. Operating income was negative at -$14.75 million, while gross profit remained positive at $26.49 million, suggesting high operating expenses relative to sales. The EV/EBITDA ratio is negative at -2.34, reflecting the lack of earnings before interest, taxes, depreciation, and amortization.

Revenue concentration and segment details are not explicitly provided in the available data, preventing a detailed analysis of geographic or product mix exposure. The company's total revenue for the latest normalized period is $37.06 million. Without specific segment breakdowns, the revenue base appears consolidated, though the lack of diversification data limits the assessment of concentration risk.

Growth trajectory analysis is constrained by the absence of historical period data in the input. The current revenue figure of $37.06 million serves as the baseline, but year-over-year or quarter-over-quarter trends cannot be calculated from the provided snapshot. The operating cash flow is negative at -$12.38 million, indicating that the company is consuming cash to fund operations, which may pressure future growth unless offset by financing activities.

Risk factors include medium liquidity risk and low dilution risk. The negative operating cash flow and high debt-to-equity ratio pose financial stability concerns. The key flag regarding negative net cash highlights the company's reliance on external financing or asset liquidation to meet obligations. The absence of strong buy or buy recommendations from analysts, with a mean recommendation of 3.00 (Hold), suggests market caution regarding the company's near-term prospects.

Recent events include a sector contamination re-analysis via the sector classification-direct path, audited on 2026-07-13. This administrative update does not reflect operational changes but ensures accurate classification. Analyst price targets range from a low of $0.75 to a high of $5.00, with a mean and median target of $2.88, indicating potential upside from the current market price of $0.372 if operational improvements are realized.

There are no new material changes, watcher signals, or cross-source dispatches to report for Cytosorbents Corp (CTSO.O) in the provided data. The system explicitly notes "no material change vs prior analysis," and the cross-source signal log shows zero dispatches for every day from June 24, 2026, through July 14, 2026. Consequently, there is no new external event or market movement to lead with. The only recorded activity involves internal revisions to the AI analysis framework, specifically within the `ha_light_thesis` source. These modifications, classified as medium severity, updated the narrative, business summary, conclusion, and key takeaways. However, these are structural or interpretive adjustments to the existing analysis model rather than responses to new corporate developments or financial results. From a fundamental standpoint, Cytosorbents Corp continues to operate without coverage from analysts or inclusion in major indices, as indicated by zero counts for both analyst and index membership. The company’s ownership structure remains concentrated, with 13 top holders identified, but there is no data suggesting any recent shifts in this composition or in the company’s officer count, which is currently listed as zero. In summary, the lack of new signals and the absence of material changes suggest a period of stability or inactivity in terms of reportable news for Cytosorbents Corp. Investors should note that the recent updates to the AI analysis fields do not reflect new factual events but rather a refinement of the existing analytical perspective. No new financial estimates, ESG updates, or relationship changes are cited in the available facts.

Free cash flow improved 63.7% year-over-year to negative $7.2 million, indicating significant operational efficiency gains.

Net income surged 60.4% year-over-year to a loss of $8.2 million, demonstrating strong profitability improvement trends.

Revenue grew 4.1% year-over-year to $37.1 million, showing top-line expansion despite broader industry headwinds.

Cash conversion ratio of 1.04 exceeds the cohort median of 0.79, highlighting superior cash management capabilities.

Current ratio of 2.13 suggests adequate short-term liquidity to meet immediate operational obligations and debts.

Debt-to-equity ratio of 2.82 places the company in the bottom quartile, signaling excessive financial leverage risk.

Revenue declined at a 3.7% CAGR over four years, suggesting long-term structural challenges in market growth.

Revenue $8.9M, +1,6% YoY; Operating income +21,7% YoY.

• ▍Revenue $8.9M, +1,6% YoY
• ▍Operating income +21,7% YoY
• ▍Net income −246,9% YoY
• ▍Free cash flow −314,9% YoY
• ▍Net margin -57.9%

Revenue $9.2M, +41,6% YoY; Operating income −22,2% YoY.

• ▍Revenue $9.2M, +41,6% YoY
• ▍Operating income −22,2% YoY
• ▍Net income +30,3% YoY
• ▍Free cash flow +30,4% YoY
• ▍Net margin -59.5%

Revenue $9.5M, +10,1% YoY; Operating income +40,8% YoY.

• ▍Revenue $9.5M, +10,1% YoY
• ▍Operating income +40,8% YoY
• ▍Net income −14,5% YoY
• ▍Free cash flow −1,8% YoY
• ▍Net margin -33.4%

Revenue $9.6M, +8,8% YoY; Operating income −1,3% YoY.

• ▍Revenue $9.6M, +8,8% YoY
• ▍Operating income −1,3% YoY
• ▍Net income +145,3% YoY
• ▍Free cash flow +156,8% YoY
• ▍Net margin 20.2%

Revenue $8.7M; Operating income -$3.9M.

• ▍Revenue $8.7M
• ▍Operating income -$3.9M
• ▍Net margin -16.9%

Revenue $6.5M; Operating income -$4.0M.

• ▍Revenue $6.5M
• ▍Operating income -$4.0M
• ▍Net margin -120.9%

Revenue $8.6M; Operating income -$4.8M.

• ▍Revenue $8.6M
• ▍Operating income -$4.8M
• ▍Net margin -32.1%

Revenue $8.8M; Operating income -$3.6M.

• ▍Revenue $8.8M
• ▍Operating income -$3.6M
• ▍Net margin -48.6%

Revenue $37.1M, +4,1% YoY; Operating income +8,8% YoY.

• ▍Revenue $37.1M, +4,1% YoY
• ▍Operating income +8,8% YoY
• ▍Net income +60,4% YoY
• ▍Free cash flow +63,7% YoY
• ▍Net margin -22.1%

Revenue $35.6M, +14,5% YoY; Operating income +47,5% YoY.

• ▍Revenue $35.6M, +14,5% YoY
• ▍Operating income +47,5% YoY
• ▍Net income +29,2% YoY
• ▍Free cash flow +31,0% YoY
• ▍Net margin -58.2%

Revenue $31.1M, −10,4% YoY; Operating income −1,4% YoY.

• ▍Revenue $31.1M, −10,4% YoY
• ▍Operating income −1,4% YoY
• ▍Net income +10,9% YoY
• ▍Free cash flow +25,2% YoY
• ▍Net margin -94.1%

Revenue $34.7M, −19,6% YoY; Operating income −38,6% YoY.

• ▍Revenue $34.7M, −19,6% YoY
• ▍Operating income −38,6% YoY
• ▍Net income −33,6% YoY
• ▍Free cash flow −36,6% YoY
• ▍Net margin -94.6%